health_text_en | Page 17 of 73

DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY

Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA…

2 มี.ค. 66 16:17

thaipr.net

2 มี.ค. 66

ClinChoice Acquires CROMSOURCE, Expanding its Global Presence

ClinChoice Medical Development is pleased to announce its acquisition of CROMSOURCE S.r.l., an ISO-certified full-service contract research organization with its corporate headquarters in Verona, Italy and its US headquarters in Cary, NC. CROMSOURCE has operational subsidiaries in the US and seven countries throughout Western and Eastern Europe, along with field-based staff across various locations in […]

2 มี.ค. 66 9:20

thaipr.net

2 มี.ค. 66

Cambrex Recognized with CDMO Leadership Awards for 9th Consecutive Year

Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized with 2023 CDMO Leadership Awards in the categories of Quality, Service, Expertise, and Compatibility. Additionally, Cambrex was selected as a “Champion” in the Service category. This marks the ninth consecutive year Cambrex has been acknowledged with an award. […]

2 มี.ค. 66 8:15

thaipr.net

2 มี.ค. 66

AMPLIFY HEALTH ASIA PTE LIMITED APPOINTS DR AXEL BAUR AS CHIEF EXECUTIVE OFFICER

Amplify Health Asia Pte Limited (Amplify Health), the pan-Asian integrated health technology solutions joint venture between AIA Group Limited and Discovery Limited, today announced the planned succession of Deputy Chief Executive Officer Dr Axel Baur to the role of Chief Executive Officer (CEO), effective immediately. Axel joined Amplify Health in March 2022 following a 26-year career at management consultancy […]

1 มี.ค. 66 9:16

thaipr.net

1 มี.ค. 66

MED-EL Presents: World Cochlear Implant Day 2023 – Over 45 years of major technological advances that enhance hearing and quality of life

Today, MED-EL, a leader in implantable hearing solutions, celebrates together with everyone living with and benefiting from cochlear implants. World Cochlear Implant Day pays tribute to the tremendous technological developments since the modern cochlear implant was first invented 45 years ago. To MED-EL, it is also reason to acknowledge the great successes: Around 1 million […]

24 ก.พ. 66 16:152023-02-24

thaipr.net

24 ก.พ. 66

CRT 2023 selects Syntach Cardiac Support System for Best Innovation Competition

Syntach AB (“Syntach”) is pleased to announce that the Company’s Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the Omni Shoreham Hotel in Washington DC, February 25 – 28, 2023. The Syntach technology […]

23 ก.พ. 66 17:00

thaipr.net

23 ก.พ. 66

Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company, today announced that the United Kingdom’s (UK) Medicines and Healthcare Products Regulatory Agency…

23 ก.พ. 66 8:04

thaipr.net

23 ก.พ. 66

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective […]

22 ก.พ. 66 8:152023-02-22

thaipr.net

22 ก.พ. 66

Synbio Tech Inc. and Cosmax Group signed an exclusive cooperation agreement to jointly expand the South Korean probiotics market

Synbio Tech Inc. and Cosmax NBT, a major South Korean biotechnology company officially signed an exclusive cooperation agreement to launch Lactobacillus plantarum TWK10® probiotic strain in South Korea, and announced that TWK10® has been approved as an Individual Health Functional Food certification by the Ministry of Food and Drug Safety of South Korea. Under the agreement, COSMAX […]

21 ก.พ. 66 15:302023-02-21

thaipr.net

21 ก.พ. 66

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

EMA Marketing Authorisation Application for leniolisib changed to standard review timetable Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has decided to shift its assessment of the Marketing Authorisation Application (MAA) for leniolisib to a standard review timetable.…

17 ก.พ. 66 8:28

thaipr.net

17 ก.พ. 66